Papa Luena, Djedaini Mansour, Martin Tiphaine C, Zangui Mahtab, Beaumont Kristin G, Sebra Robert, Parsons Ramon, Schaniel Christoph, Hoffman Ronald
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Front Cell Dev Biol. 2020 Dec 15;8:592348. doi: 10.3389/fcell.2020.592348. eCollection 2020.
expansion strategies of human hematopoietic stem cell (HSC) grafts with suboptimal stem cell dose have emerged as promising strategies for improving outcomes of HSC transplantation in patients with hematological malignancies. While exposure of HSCs to cultures expands the number of phenotypically identifiable HSCs, it frequently alters the transcriptomic and metabolic profiles, therefore, compromising their long-term (LT) hematopoietic reconstitution capacity. Within the heterogeneous pool of expanded HSCs, the precise phenotypic, transcriptomic and metabolic profile and thus, the identity of HSCs that confer LT repopulation potential remains poorly described. Utilizing valproic acid (VPA) in cultures of umbilical cord blood (UCB)-CD34 cells, we demonstrate that expanded HSCs phenotypically marked by expression of the stem cell markers CD34, CD90 and EPCR (CD201) are highly enriched for LT-HSCs. Furthermore, we report that low mitochondrial membrane potential, and, hence, mitochondrial activity distinguishes LT-HSCs within the expanded pool of phenotypically defined HSCs. Remarkably, such reduced mitochondrial activity is restricted to cells with the highest expression levels of CD34, CD90 and EPCR phenotypic markers. Together, our findings reveal that high expression of CD34, CD90 and EPCR in conjunction with low mitochondrial activity is critical for identification of functional LT-HSCs generated within expansion cultures.
对于造血干细胞(HSC)剂量次优的人类造血干细胞移植,其扩增策略已成为改善血液系统恶性肿瘤患者造血干细胞移植结局的有前景的策略。虽然将造血干细胞置于培养环境中可增加表型可识别的造血干细胞数量,但这常常会改变转录组和代谢谱,从而损害其长期(LT)造血重建能力。在扩增的造血干细胞异质池中,具有LT重建潜力的造血干细胞的精确表型、转录组和代谢谱,以及其特性仍描述甚少。在脐血(UCB)-CD34细胞培养中使用丙戊酸(VPA),我们证明,以干细胞标志物CD34、CD90和EPCR(CD201)表达为表型特征的扩增造血干细胞高度富集了LT-HSC。此外,我们报告,低线粒体膜电位,进而线粒体活性,可区分表型定义的扩增造血干细胞库中的LT-HSC。值得注意的是,这种降低的线粒体活性仅限于CD34、CD90和EPCR表型标志物表达水平最高的细胞。总之,我们的研究结果表明,CD34、CD90和EPCR的高表达与低线粒体活性相结合,对于鉴定在体外扩增培养中产生的功能性LT-HSC至关重要。